- Home
- SYNA vs CELC Comparison
SYNA vs CELC Comparison
Compare SYNA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SYNA | CELC |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 2002 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SYNA | CELC |
|---|---|---|
| Price | $77.54 | $105.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $89.13 | ★ $100.13 |
| AVG Volume (30 Days) | 480.5K | ★ 945.1K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,109,100,000.00 | N/A |
| Revenue This Year | $11.70 | N/A |
| Revenue Next Year | $11.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.24 | N/A |
| 52 Week Low | $41.80 | $7.58 |
| 52 Week High | $89.81 | $112.64 |
Technical Indicators
Market Signals| Indicator | SYNA | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 62.06 | 70.65 |
| Support Level | $66.86 | $100.00 |
| Resistance Level | $81.85 | $108.91 |
| Average True Range (ATR) | 2.50 | 5.14 |
| MACD | 1.26 | -0.88 |
| Stochastic Oscillator | 76.36 | 54.47 |
Price Performance
Historical ComparisonAbout SYNA Synaptics Incorporated $0.001 Par Value
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. It operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. The company geographically, it derives a majority of revenue from China, and also has its presence in Taiwan, Japan, South Korea, United States and Other countries.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.